SKŘIČKOVÁ, Jana, Zbyněk BORTLÍČEK, Karel HEJDUK, M. PEŠEK, V. KOLEK, L. KOUBKOVÁ, Marcela TOMÍŠKOVÁ, J. ROUBEC, P. ZATLOUKAL and F. SALAJKA. Use of pemetrexed as first line treatment of advanced non-small cell lung cancer: The Czech Republic experience with the treatment of 237 patients (pts). In 13th Central European Lung Cancer Conference. 2012. ISSN 0169-5002. doi:10.1016/j.lungcan.2012.05.074.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Use of pemetrexed as first line treatment of advanced non-small cell lung cancer: The Czech Republic experience with the treatment of 237 patients (pts)
Authors SKŘIČKOVÁ, Jana (203 Czech Republic, guarantor, belonging to the institution), Zbyněk BORTLÍČEK (203 Czech Republic, belonging to the institution), Karel HEJDUK (203 Czech Republic, belonging to the institution), M. PEŠEK (203 Czech Republic), V. KOLEK (203 Czech Republic), L. KOUBKOVÁ (203 Czech Republic), Marcela TOMÍŠKOVÁ (203 Czech Republic, belonging to the institution), J. ROUBEC (203 Czech Republic), P. ZATLOUKAL (203 Czech Republic) and F. SALAJKA (203 Czech Republic).
Edition 13th Central European Lung Cancer Conference, 2012.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30200 3.2 Clinical medicine
Country of publisher Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.392
RIV identification code RIV/00216224:14110/12:00060610
Organization unit Faculty of Medicine
ISSN 0169-5002
Doi http://dx.doi.org/10.1016/j.lungcan.2012.05.074
UT WoS 000305842300075
Keywords in English lung cancer; erlotinib
Changed by Changed by: prof. MUDr. Jana Skřičková, CSc., učo 1808. Changed: 14. 2. 2013 22:10.
Abstract
The Czech Republic has had an opportunity to use pemetrexed for 1st line treatment of advanced NSCLC from the year 2008. The purpose of this trial was to evaluate the activity and feasibility of pemetrexed in 1st line treatment NSCLC patients.
PrintDisplayed: 21. 5. 2022 21:08